Archive: News
-
TGen leader earns award for advances in treating pancreatic cancer
Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief of the Translational Genomics Research Institute (TGen), an affiliate of the City of Hope, is one of five leading researchers who will receive a Luminary Award in GI Cancers from OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers.
Category: News
-
Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC
The combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and the VEGF inhibitor bevacizumab (Avastin) showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma (HCC).
Category: News
-
Update on HCC treatment by Dr. Aiwu Ruth He
Dr. Aiwu Ruth He summarizes the highlights of ILCA 2018 and provides updates in HCC treatment.
Category: News
-
OncLive® and The Ruesch Center to Host the Second Annual Luminary Awards in GI Cancers
The awards honor individuals who are making a difference in the gastrointestinal cancers community.
Category: News
-
OncLive® and The Ruesch Center Announce the Honorees of The Luminary Awards in GI Cancers
Honorees are recognized for their tremendous devotion and leadership in research, clinical care and advocacy in GI cancer.
Category: News
-
OncLive and The Ruesch Center Announce the Inaugural Luminary Awards in Gastrointestinal Cancer
The first annual Luminary Awards in GI Cancers honoring five outstanding individuals who have devoted their time, talent and resources to improving the care for patients and families affected by GI cancers, will be presented Friday, Dec. 1 at the 8th Annual Ruesch Center Symposium: Fighting a Smarter War on Cancer in Washington.
Category: News
-
Deep, Durable Responses Seen With Atezolizumab Combo For Frontline HCC Treatment
Strong efficacy signals and a tolerable safety profile were observed with the combination of atezolizumab and bevacizumab in the first-line treatment of patients with unresectable or metastatic HCC.
Category: News
-
At Cancer Bell-Ringing Ceremonies, Some Are Angry Onlookers
Bell-ringing ceremonies to mark the end of a cancer treatment are now widespread at cancer clinics around the US. For metastatic cancer patients, who cannot “beat” cancer, the sound of the bell can trigger anger, resentment, resignation, or depression.
Category: News
-
Treating GI Cancers with Proton Therapy: Ask Dr. Keith Unger
Keith Unger, MD, is a Board-certified radiation oncologist, who specializes in the use of proton therapy and other radiation treatments for gastrointestinal cancers at MedStar Georgetown University Hospital.
Category: News
-
Treating a Rare Gastrointestinal Cancer: Meeghan DeCagna’s Story
When Meeghan DeCagna was diagnosed with a rare GI cancer, called a GIST, and targeted therapy was unsuccessful, her only option was surgery to remove a six pound tumor. She found Director of Surgical Oncology at MedStar Georgetown, Waddah Al-Refaie, MD to lead her complicated operation.
Category: News